OpenAI launches AI browser Atlas | The Jerusalem PostJerusalem Post/Business & InnovationThe browser is now available globally on Apple’s macOS. It will soon be made available on Windows, iOS, and Android. OpenAI logo is seen in this illustration…
Category: 6. Business
-
OpenAI launches AI browser Atlas
-
Centerbridge seeks Clal Insurance stake
Having sold its stake in The Phoenix, the US investment firm is looking to return to Israel’s insurance and financial sector.
Continue Reading
-
BCG appoints new chief risk officer after Gaza aid controversy
Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Boston Consulting Group has appointed a new chief risk officer to oversee tougher internal controls and whistleblower…
Continue Reading
-
3M’s stock hits a four-year high as sales, profits and the outlook keep improving
By Tomi Kilgore
Parent of Post-it Notes, Scotch tape sees consumer business grow for a fourth straight quarter despite a ‘relatively weak consumer market’
3M’s stock was heading for a four-year high after the company’s profit…
Continue Reading
-
Journal of Medical Internet Research
Introduction
Background
Large language models (LLMs) represent a breakthrough in artificial intelligence (AI), capable of processing, understanding, and generating humanlike language at scale. With their advanced natural language processing…
Continue Reading
-
HLC43 Nets FDA Orphan Drug Designation in Thymic Epithelial Tumors
The PD-L1–directed antibody-drug conjugate (ADC) HLX43 has received orphan drug designation from the FDA for the treatment of patients with thymic epithelial tumors.1
At a data cutoff of June 28, 2025, findings from a phase 1 study…
Continue Reading
-
Elinzanetant Reduces Frequency, Severity of VMS in Differing Female Populations
This content was independently produced by Pharmacy Times in partnership with Bayer Healthcare.
When treating women across different populations, 120 mg of elinzanetant (Bayer Healthcare) reduced the frequency and severity of moderate-to-severe…
Continue Reading
-
Long-Term DeFi Data Confirm Durable Efficacy and Consistent Safety of Nirogacestat in Desmoid Tumors
Long-term findings from the phase 3 DeFi trial (NCT03785964) demonstrated sustained efficacy and a consistent safety profile with nirogacestat (Ogsiveo), an oral γ-secretase inhibitor, for the treatment of adult patients with progressing…
Continue Reading
-
Israel generative AI co Moonshot raises $10m
The company has developed a no-code platform that leverages generative AI to teach websites to evolve independently to increase conversions, sales, and revenue.
Continue Reading
